Protagonist Therapeutics, INC (PTGX) — SEC Filings

Overview

Protagonist Therapeutics, INC (PTGX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 144 filed on Mar 26, 2026: Harold E. Selick, a reporting person associated with Protagonist Therapeutics, Inc., filed a Form 144 on March 26, 2026, indicating the proposed sale of securities. The filing does not specify the number of shares or dollar amount involved in the transaction.

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Protagonist Therapeutics, INC is neutral.

Filing Type Overview

Protagonist Therapeutics, INC (PTGX) has filed 1 4, 2 144, 6 10-Q, 18 8-K, 2 DEF 14A, 1 8-K/A, 2 10-K, 12 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• Protagonist Therapeutics: Proposed Securities Sale — 144 · Mar 26, 2026 Risk: low
  Harold E. Selick, a reporting person associated with Protagonist Therapeutics, Inc., filed a Form 144 on March 26, 2026, indicating the proposed sale of securit
• Protagonist Therapeutics Insider Files Form 4 on March 25, 2026 — 4 · Mar 25, 2026
  This Form 4 filing from Protagonist Therapeutics, Inc. (PTGX) indicates that Dr. Dinesh V. Patel, a reporting person, filed a statement of changes in beneficial
• Protagonist Therapeutics Insider Dr. Dinesh Patel Files for Stock Sale — 144 · Mar 24, 2026
  This 144 filing indicates that Dinesh V. Patel, Ph.D., a reporting person associated with Protagonist Therapeutics, Inc., intends to sell securities. While the
• Protagonist Swings to Loss on Plummeting Collaboration Revenue — 10-Q · Nov 6, 2025 Risk: medium
  Protagonist Therapeutics, Inc. (PTGX) reported a significant decline in revenue and a net loss for the nine months ended September 30, 2025, primarily due to a
• Protagonist Therapeutics Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, as well as financial statements a
• Protagonist's Q2 Loss Widens to $35.2M Amid Rusfertide Development — 10-Q · Aug 6, 2025 Risk: high
  Protagonist Therapeutics, Inc. reported a net loss of $35.2 million for the quarter ended June 30, 2025, a significant increase from the $28.5 million net loss
• Protagonist Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 26, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on matters submitted to a vote of security holders as of June 20, 2025. The filing does
• Protagonist Therapeutics Files 8-K on Financials — 8-K · May 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• Protagonist Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates.
• Protagonist Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 20, 2025. The filing outlines th
• Protagonist Therapeutics Files 8-K — 8-K · Mar 20, 2025 Risk: low
  On March 17, 2025, Protagonist Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporat
• Protagonist Therapeutics Files 8-K/A Amendment — 8-K/A · Mar 11, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K/A on March 11, 2025, to amend a previous filing. The amendment pertains to financial statements and exhibits, with t
• Protagonist Therapeutics Files 8-K — 8-K · Mar 10, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on March 10, 2025, reporting other events and financial statements as of March 8, 2025. The filing does not contain
• Protagonist Therapeutics Files 8-K — 8-K · Mar 3, 2025 Risk: low
  On March 3, 2025, Protagonist Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
• Protagonist Therapeutics Files 8-K on Financials — 8-K · Feb 21, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on February 21, 2025, reporting on its results of operations and financial condition, and providing financial statem
• Protagonist Therapeutics Files 2024 10-K — 10-K · Feb 21, 2025 Risk: medium
  Protagonist Therapeutics, Inc. filed its 2024 10-K on February 21, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The c
• Protagonist Therapeutics Announces Executive and Director Compensation Changes — 8-K · Jan 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. announced on January 1, 2025, changes in its executive and director compensation arrangements. The filing details the election of
• Protagonist Therapeutics Files 8-K: Material Agreement — 8-K · Nov 18, 2024 Risk: medium
  On November 13, 2024, Protagonist Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also notes other events and includes financial sta
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Protagonist Therapeutics Files 8-K — 8-K · Nov 7, 2024 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as financial statements
• Protagonist Therapeutics Q3 2024 Update: Cash Up, Financing Activities Detailed — 10-Q · Nov 7, 2024 Risk: medium
  Protagonist Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $57.7 million as of De
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G Filing — SC 13G · Oct 16, 2024
• Protagonist Therapeutics Appoints New CMO, Adds Director — 8-K · Sep 20, 2024 Risk: medium
  Protagonist Therapeutics, Inc. announced on September 17, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sar
• SC 13G/A Filing — SC 13G/A · Aug 7, 2024
• Protagonist Therapeutics Files 8-K — 8-K · Aug 6, 2024 Risk: low
  On August 6, 2024, Protagonist Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations
• Protagonist Therapeutics Q2 2024: Net Loss of $24.1M — 10-Q · Aug 6, 2024 Risk: medium
  Protagonist Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $57.7 million and total liabilities of $
• Protagonist Therapeutics Elects Directors, Ratifies Auditors — 8-K · Jun 26, 2024 Risk: low
  On June 20, 2024, Protagonist Therapeutics, Inc. filed an 8-K report detailing the results of its 2024 Annual Meeting of Stockholders. The company announced the
• Protagonist Therapeutics Files 8-K on Financials — 8-K · May 7, 2024 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Protagonist Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
  Protagonist Therapeutics, Inc (PTGX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Protagonist Therapeutics, Inc. filed a 10-Q report for the per
• Protagonist Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders on June 20, 2024 — DEF 14A · Apr 26, 2024 Risk: low
  Protagonist Therapeutics, Inc (PTGX) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Protagonist Therapeutics, Inc. will hold its 2024 Annual
• Protagonist Therapeutics Files 8-K for Financial Results — 8-K · Feb 27, 2024 Risk: medium
  Protagonist Therapeutics, Inc. filed an 8-K on February 27, 2024, to report its results of operations and financial condition, along with related financial stat
• Protagonist Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  Protagonist Therapeutics, Inc (PTGX) filed a Annual Report (10-K) with the SEC on February 27, 2024. Protagonist Therapeutics, Inc. filed its annual report on F
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Adage Capital Partners Amends Protagonist Therapeutics Stake — SC 13G/A · Feb 7, 2024
  Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, indicating a change in their ownership of Protagonist Therapeutics, Inc. common stoc
• Farallon Capital Amends Protagonist Therapeutics Stake — SC 13G/A · Feb 2, 2024
  Farallon Capital Partners, L.P. filed an amended Schedule 13G/A on February 2, 2024, indicating a change in their ownership of Protagonist Therapeutics, Inc. co
• Protagonist Therapeutics Enters Material Definitive Agreement — 8-K · Jan 31, 2024
  Protagonist Therapeutics, Inc. filed an 8-K on January 31, 2024, to report an "Entry into a Material Definitive Agreement." This filing indicates that the compa
• BlackRock Amends Protagonist Therapeutics Stake to 4M Shares — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, disclosing its ownership in Protagonist Therapeutics, Inc. As of December 31, 2023, BlackRock repo
• State Street Corp Updates Passive Stake in Protagonist Therapeutics — SC 13G/A · Jan 23, 2024
  State Street Corp filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Protagonist Therapeutics Inc (PTGX) common stock as of December 31,
• Protagonist Therapeutics Signals Potential Strategic Activity via 8-K — 8-K · Jan 16, 2024
  Protagonist Therapeutics, Inc. filed an 8-K on January 16, 2024, reporting an event that occurred on January 9, 2024. This filing indicates the company is using
• Protagonist Therapeutics Files Routine 8-K for Disclosure — 8-K · Jan 8, 2024
  Protagonist Therapeutics, Inc. filed an 8-K on January 8, 2024, indicating a routine filing for Regulation FD Disclosure and Financial Statements and Exhibits.

Related Companies

JNJ · TAK

Frequently Asked Questions